Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Position in Protagonist Therapeutics, Inc. $PTGX

Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 123.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 90,317 shares of the company’s stock after buying an additional 49,833 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.15% of Protagonist Therapeutics worth $6,000,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Commodore Capital LP bought a new stake in shares of Protagonist Therapeutics in the second quarter worth $59,415,000. Adage Capital Partners GP L.L.C. boosted its position in Protagonist Therapeutics by 218.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,092,262 shares of the company’s stock worth $60,369,000 after purchasing an additional 748,758 shares during the last quarter. BVF Inc. IL grew its stake in shares of Protagonist Therapeutics by 24.7% during the 2nd quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock valued at $177,474,000 after purchasing an additional 636,026 shares during the period. Holocene Advisors LP purchased a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at about $29,311,000. Finally, State Street Corp lifted its stake in shares of Protagonist Therapeutics by 18.5% in the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after purchasing an additional 500,924 shares during the period. 98.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PTGX has been the subject of a number of research reports. Truist Financial upped their target price on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a report on Monday, January 5th. JPMorgan Chase & Co. boosted their price objective on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating and set a $82.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Finally, Weiss Ratings upgraded shares of Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, December 24th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Protagonist Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $86.77.

Protagonist Therapeutics Stock Down 1.0%

PTGX stock opened at $82.30 on Tuesday. Protagonist Therapeutics, Inc. has a 52 week low of $33.70 and a 52 week high of $96.54. The company has a fifty day simple moving average of $86.51 and a two-hundred day simple moving average of $72.20. The firm has a market capitalization of $5.15 billion, a P/E ratio of 132.74 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The company had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. As a group, analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Insider Activity at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 34,438 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $82.48, for a total transaction of $2,840,446.24. Following the transaction, the chief executive officer directly owned 580,505 shares in the company, valued at approximately $47,880,052.40. This represents a 5.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Asif Ali sold 8,588 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $82.48, for a total value of $708,338.24. Following the completion of the sale, the chief financial officer owned 78,077 shares in the company, valued at approximately $6,439,790.96. The trade was a 9.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 52,540 shares of company stock worth $4,333,499. Insiders own 4.90% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.